Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Osteoporosis in men is an increasingly recognized problem with associated fracture morbidity and mortality. Treatment is limited, with the bisphosphonates being the mainstay of therapy. Risedronate has demonstrated fracture efficacy in women and efficacy has been recently been investigated in men. In men, risedronate either maintains or increases bone mineral density. In placebo controlled trials it has been shown to be safe and effective in preventing fractures.
Department of Medicine, St. Joseph's Healthcare, McMaster University, Hamilton, ON, Canada.
Raja
R
Bobba
Jonathan D
JD
Adachi
D000305:Adrenal Cortex Hormones / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D050723:Fractures, Bone / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000068296:Risedronic Acid; D012307:Risk Factors; D016896:Treatment Outcome
D000305:Adrenal Cortex Hormones; D050071:Bone Density Conservation Agents; D000068296:Risedronic Acid; D012968:Etidronic Acid